Skip to main content
. 2022 Feb;11(2):201–212. doi: 10.21037/tlcr-22-49

Figure 2.

Figure 2

Investigator-assessed efficacy of nivolumab combined with rh-endostatin. (A) Best responses in efficacy-evaluable patients (n=31). (B) Duration of treatment in patients with objective response (n=22). PR, partial response; SD, stable disease; PD, progressive disease.